CA2198891A1 - Lymphocytes t modifies genetiquement - Google Patents

Lymphocytes t modifies genetiquement

Info

Publication number
CA2198891A1
CA2198891A1 CA002198891A CA2198891A CA2198891A1 CA 2198891 A1 CA2198891 A1 CA 2198891A1 CA 002198891 A CA002198891 A CA 002198891A CA 2198891 A CA2198891 A CA 2198891A CA 2198891 A1 CA2198891 A1 CA 2198891A1
Authority
CA
Canada
Prior art keywords
cell
epitope
cells
poly
cell according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002198891A
Other languages
English (en)
Inventor
Hartmut Wekerle
Hans Thoenen
Rainer Kramer
Yiping Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2198891A1 publication Critical patent/CA2198891A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des lymphocytes T matures modifiés génétiquement, contenant des récepteurs autoréactifs et comportant dans leur génome au moins un gène, introduit de l'extérieur, pouvant exprimer un (poly)peptide. L'invention concerne en outre des médicaments contenant ces lymphocytes T.
CA002198891A 1994-08-31 1995-08-30 Lymphocytes t modifies genetiquement Abandoned CA2198891A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DEP4431011.0 1994-08-31
DE4431011 1994-08-31
US154795P 1995-07-27 1995-07-27
US60/001,547 1995-07-27

Publications (1)

Publication Number Publication Date
CA2198891A1 true CA2198891A1 (fr) 1996-03-07

Family

ID=6527072

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002198891A Abandoned CA2198891A1 (fr) 1994-08-31 1995-08-30 Lymphocytes t modifies genetiquement

Country Status (5)

Country Link
EP (1) EP0782627A1 (fr)
JP (1) JPH10505235A (fr)
AU (1) AU3474595A (fr)
CA (1) CA2198891A1 (fr)
WO (1) WO1996006942A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
EP0824594B1 (fr) * 1995-05-04 2005-04-06 The United States of America as Representend by The Secretary of the Navy Procedes ameliores de transfection des lymphocytes t

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5188959A (en) * 1989-09-28 1993-02-23 Trustees Of Tufts College Extracellular matrix protein adherent t cells
WO1992005794A1 (fr) * 1990-09-28 1992-04-16 Immunex Corporation Methode servant a produire des lymphocytes t cytotoxiques th-independants

Also Published As

Publication number Publication date
EP0782627A1 (fr) 1997-07-09
AU3474595A (en) 1996-03-22
JPH10505235A (ja) 1998-05-26
WO1996006942A1 (fr) 1996-03-07

Similar Documents

Publication Publication Date Title
CA2189778C (fr) Utilisation du ligand fas comme depresseur des reponses immunitaires a mediation lymphocytaire
Kramer et al. Gene transfer through the blood–nerve barrier: NGF-engineered neuritogenic T lymphocytes attenuate experimental autoimmune neuritis
Ghivizzani et al. Direct retrovirus-mediated gene transfer to the synovium of the rabbit knee: implications for arthritis gene therapy
US6683058B1 (en) Methods for therapy of neurodegenerative disease of the brain
CA2216878A1 (fr) Vecteurs viraux et leur utilisation pour traiter des maladies hyperproliferatives, en particulier, la restenose
US20110111505A1 (en) Genetically engineered cells which express bone morphogenic proteins
US6451306B1 (en) Methods for therapy of neurodegenerative disease of the brain
Sasaki et al. Retrovirus producer cells encoding antisense VEGF prolong survival of rats with intracranial GS9L gliomas
US20020187936A1 (en) Methods of treating liver disease and liver damage with growth hormone and foxM1B
AU752676B2 (en) Method for the treatment or diagnosis of human pathologies with disseminated or difficult to access cells or tissues
Haase et al. Therapeutic benefit of ciliary neurotrophic factor in progressive motor neuronopathy depends on the route of delivery
WO2002036078A2 (fr) Ciblage de cellules souches pluripotentielles dans des tissus
US7807145B2 (en) Method of inducing neuronal production in the brain and spinal cord
Frechilla et al. Implanted BDNF-producing fibroblasts prevent neurotoxin-induced serotonergic denervation in the rat striatum
EP1307582B1 (fr) Produits de recombinaison d'acide nucleique, cellules vasculaires transformees au moyen de ces produits de recombinaison, compositions pharmaceutiques et procedes les mettant en application afin d'induire l'angiogenese
US20040109844A1 (en) Methods of treating age-related defects and diseases
JPH10505235A (ja) 遺伝学的に改変されたｔ細胞
CZ250499A3 (cs) Použití nukleové kyseliny k indukci inervace svalů a růstu axonů motorických neuronů
US7105156B1 (en) Method of using an adenoviral vector encoding a retinoblastoma protein to treat hyperproliferating cells
JP2000515137A (ja) 軸索の成長を制御する方法
Kitagawa et al. Induction of DNA fragmentation and HSP72 immunoreactivity by adenovirus‐mediated gene transfer in normal gerbil hippocampus and ventricle
KR102770127B1 (ko) 이종 면역세포에 대한 화학주성을 유도하는 형질전환된 면역세포
Isacson et al. Cell-mediated delivery of neurotrophic factors and neuroprotection in the neostriatum and substantia nigra
WO2000027198A1 (fr) Vecteurs retroviraux codant l'interferon alpha et utilisations de ces derniers
WO1995015177A2 (fr) Renforcement de l'efficacite des cytokines a helice alpha

Legal Events

Date Code Title Description
FZDE Dead